Innate lymphoid cells: NK and cytotoxic ILC3 subsets infiltrate metastatic breast cancer lymph nodes.


Journal

Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526

Informations de publication

Date de publication:
2022
Historique:
entrez: 4 4 2022
pubmed: 5 4 2022
medline: 6 4 2022
Statut: epublish

Résumé

Innate lymphoid cells (ILCs) - which include cytotoxic Natural Killer (NK) cells and helper-type ILC - are important regulators of tissue immune homeostasis, with possible roles in tumor surveillance. We analyzed ILC and their functionality in human lymph nodes (LN). In LN, NK cells and ILC3 were the prominent subpopulations. Among the ILC3s, we identified a CD56

Identifiants

pubmed: 35371620
doi: 10.1080/2162402X.2022.2057396
pii: 2057396
pmc: PMC8973349
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2057396

Informations de copyright

© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.

Déclaration de conflit d'intérêts

No potential conflict of interest was reported by the author(s).

Références

Nat Immunol. 2013 Mar;14(3):221-9
pubmed: 23334791
EMBO J. 2004 Jan 28;23(2):255-9
pubmed: 14685277
Autophagy. 2017 Mar 4;13(3):633-636
pubmed: 28103115
J Mammary Gland Biol Neoplasia. 2020 Sep;25(3):191-203
pubmed: 33034778
Nat Rev Immunol. 2003 Oct;3(10):781-90
pubmed: 14523385
Cell Oncol (Dordr). 2020 Feb;43(1):1-18
pubmed: 31900901
Immunity. 2018 Feb 20;48(2):396-398
pubmed: 29466761
J Exp Med. 2008 Dec 22;205(13):2965-73
pubmed: 19029380
Oncoimmunology. 2013 Jan 1;2(1):e22647
pubmed: 23482441
Blood. 2014 Jul 31;124(5):700-9
pubmed: 24778151
Clin Cancer Res. 2019 Jul 1;25(13):4026-4037
pubmed: 30979738
Immunity. 2010 Jun 25;32(6):803-14
pubmed: 20620944
Immunity. 2010 Nov 24;33(5):736-51
pubmed: 21093318
Gene Ther. 2018 Jun;25(3):165-175
pubmed: 29880908
Int Rev Immunol. 2021;40(3):197-216
pubmed: 33258393
Cell. 2017 Mar 9;168(6):1086-1100.e10
pubmed: 28283063
Nat Immunol. 2016 Aug 19;17(9):1025-36
pubmed: 27540992
Front Immunol. 2018 Oct 11;9:2324
pubmed: 30364222
Immunity. 2013 Jun 27;38(6):1223-35
pubmed: 23791642
Cancer Res. 2017 Mar 1;77(5):1083-1096
pubmed: 28082403
Eur J Immunol. 2021 Apr;51(4):811-823
pubmed: 33300130
J Exp Med. 2010 Feb 15;207(2):281-90
pubmed: 20142432
Sci Transl Med. 2020 Sep 30;12(563):
pubmed: 32998971
Cell Mol Immunol. 2016 Sep;13(5):628-39
pubmed: 26277898
Nature. 2006 Mar 23;440(7083):540-4
pubmed: 16525420
Blood. 2009 Apr 23;113(17):4008-10
pubmed: 19244159
J Mol Med (Berl). 2015 Nov;93(11):1173-84
pubmed: 26489604
Nat Commun. 2015 Jan 09;6:5862
pubmed: 25575242
Semin Immunol. 2019 Feb;41:101274
pubmed: 31072659
Blood. 2003 Apr 15;101(8):3052-7
pubmed: 12480696
Curr Opin Immunol. 2003 Jun;15(3):308-14
pubmed: 12787756
Immunity. 2019 Feb 19;50(2):505-519.e4
pubmed: 30770247
Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):10961-6
pubmed: 20534450
Nature. 2017 Jan 12;541(7636):233-236
pubmed: 28052056
Immunity. 2018 Sep 18;49(3):464-476.e4
pubmed: 30193847
Nature. 2021 Jun;594(7864):566-571
pubmed: 34079127
Semin Immunol. 2014 Apr;26(2):132-7
pubmed: 24661538
J Exp Med. 2017 Aug 7;214(8):2331-2347
pubmed: 28698286
Cancer Immunol Res. 2019 Feb;7(2):208-218
pubmed: 30514793
Curr Protoc Cytom. 2010 Jul;Chapter 10:Unit10.17
pubmed: 20578106
Cancer Res. 2011 Nov 1;71(21):6621-32
pubmed: 21937679
Semin Immunol. 2021 Feb;52:101424
pubmed: 33272899
Front Immunol. 2015 Nov 30;6:605
pubmed: 26648934
Nat Commun. 2015 Sep 23;6:8280
pubmed: 26395069
Annu Rev Immunol. 2002;20:853-85
pubmed: 11861620
J Immunol. 2014 Apr 15;192(8):3805-15
pubmed: 24646734
Blood Adv. 2019 Nov 26;3(22):3674-3687
pubmed: 31765481
Front Immunol. 2012 Apr 09;3:72
pubmed: 22566953
Nat Rev Immunol. 2011 Sep 23;11(10):658-71
pubmed: 21941294
Immunity. 2018 May 15;48(5):1060
pubmed: 29768165
Blood Adv. 2017 Dec 14;1(27):2679-2691
pubmed: 29296921
Cancer Cell. 2017 Aug 14;32(2):135-154
pubmed: 28810142
Front Immunol. 2020 May 12;11:812
pubmed: 32477340
Cell. 2021 Sep 16;184(19):5015-5030.e16
pubmed: 34407392
J Clin Invest. 2011 Sep;121(9):3609-22
pubmed: 21841316
Cell Rep. 2017 Oct 17;21(3):823-833
pubmed: 29045847
Immunity. 2013 Apr 18;38(4):769-81
pubmed: 23453631
Annu Rev Immunol. 2001;19:197-223
pubmed: 11244035
Immunity. 2017 Jan 17;46(1):148-161
pubmed: 27986455
J Immunol. 2013 Mar 1;190(5):2424-36
pubmed: 23359508
Cell Mol Immunol. 2021 May;18(5):1290-1304
pubmed: 33239726
Immunol Cell Biol. 2014 Mar;92(3):237-44
pubmed: 24343663
Cancers (Basel). 2020 Dec 10;12(12):
pubmed: 33321719
Nat Immunol. 2014 May;15(5):431-8
pubmed: 24658051
Annu Rev Immunol. 2012;30:69-94
pubmed: 22149932
JCI Insight. 2018 Dec 6;3(23):
pubmed: 30518694
Front Immunol. 2019 Dec 03;10:2816
pubmed: 31849984
BMC Cancer. 2018 Mar 27;18(1):341
pubmed: 29587679

Auteurs

Louise Rethacker (L)

INSERM U1160, Institut de Recherche Saint-Louis, Hôpital Saint Louis, Paris, France.

Maxime Boy (M)

INSERM U1160, Institut de Recherche Saint-Louis, Hôpital Saint Louis, Paris, France.

Valeria Bisio (V)

INSERM U1160, Institut de Recherche Saint-Louis, Hôpital Saint Louis, Paris, France.

France Roussin (F)

Service d'Anesthésie-Réanimation, AP-HP, Hôpital Saint-Louis, Paris, France.

Jordan Denizeau (J)

INSERM U932, Département de Recherche Translationelle, Institut Curie, Université de Recherche Paris Sciences & Lettres (PSL), Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France.

Anne Vincent-Salomon (A)

Diagnostic and Theranostic Medicine Division, Institut Curie, PSL Research University, Paris, France.

Edith Borcoman (E)

Department of Medical Oncology, Institut Curie, Paris, France.
Université Paris Diderot, Université de Paris, Paris, France.

Christine Sedlik (C)

INSERM U932, Département de Recherche Translationelle, Institut Curie, Université de Recherche Paris Sciences & Lettres (PSL), Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France.

Eliane Piaggio (E)

INSERM U932, Département de Recherche Translationelle, Institut Curie, Université de Recherche Paris Sciences & Lettres (PSL), Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France.

Antoine Toubert (A)

INSERM U1160, Institut de Recherche Saint-Louis, Hôpital Saint Louis, Paris, France.
Université Paris Diderot, Université de Paris, Paris, France.
Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis, Laboratoire d'Immunologie et Histocompatibilité, Paris, France.

Nicolas Dulphy (N)

INSERM U1160, Institut de Recherche Saint-Louis, Hôpital Saint Louis, Paris, France.
Université Paris Diderot, Université de Paris, Paris, France.
Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis, Laboratoire d'Immunologie et Histocompatibilité, Paris, France.

Anne Caignard (A)

INSERM U1160, Institut de Recherche Saint-Louis, Hôpital Saint Louis, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH